TBC1D20: A Promising Drug Target and Biomarker (G128637)

Target Name: TBC1D20

NCBI ID: G128637

TBC1D20

TBC1D20: A Promising Drug Target and Biomarker

TBC1D20 (TBC20_HUMAN), a novel gene expressed in human tissues, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique expression pattern and biological activity make it an attractive candidate research object.

The expression level of TBC1D20 gene varies in different tissues and disease states. Under normal circumstances, TBC1D20 is only expressed in the liver and kidney, but its expression is significantly increased in tumor tissues and neurodegenerative diseases. In addition, the expression level of TBC1D20 is also related to factors related to various diseases, such as age, gender, body mass index, inflammatory markers, etc. These factors have a significant impact on TBC1D20 expression levels and disease risk.

The biological activity of TBC1D20 also indicates its great potential as a drug target. The expression of TBC1D20 in various tumor cell lines has been confirmed to inhibit the proliferation and metastasis of tumor cells. At the same time, TBC1D20 can also regulate the differentiation and function of immune cells, thereby improving the anti-tumor ability of the immune system. In addition, TBC1D20 can also regulate inflammatory responses, thereby reducing tissue damage caused by inflammatory diseases.

As an emerging drug target, TBC1D20 is of great significance in drug development and disease treatment. First, TBC1D20 can serve as an important therapeutic target for tumors and neurodegenerative diseases, providing new treatment options for clinical patients. Secondly, TBC1D20 can also be used as a potential therapeutic target for inflammatory diseases, providing new treatment methods for patients.

In summary, TBC1D20 has great potential as an emerging drug target. Through further research, TBC1D20 can provide new treatments and drugs for tumors and neurodegenerative diseases, bringing greater benefits to human health.

Protein Name: TBC1 Domain Family Member 20

Functions: GTPase-activating protein specific for Rab1 and Rab2 small GTPase families for which it can accelerate the intrinsic GTP hydrolysis rate by more than five orders of magnitude (PubMed:23236136). Involved in maintaining endoplasmic reticulum structure (PubMed:24891604)

The "TBC1D20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets